SINOPHARM GROUP CO. LTD. Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
SINOPHARM GROUP CO. LTD.*國藥控股股份有限公司
(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099) ANNOUNCEMENTPursuant to the rules of the National Association of Financial Market Institutional Investors and the Shanghai Stock Exchange, Sinopharm Group Co. Ltd. (the "Company") is required to publish the quarterly financial information of the Company and its subsidiaries (the "Group") which consists of consolidated balance sheet, consolidated income statement and consolidated cash flow statement of the Group, and to publish the quarterly financial information of the Company which consists of balance sheet, income statement and cash flow statement of the Company.
This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
The board of directors of the Company is pleased to announce the unaudited financial information of the Group and of the Company for the three months ended 31 March 2017 prepared in accordance with the PRC GAAP.
CONSOLIDATED FINANCIAL INFORMATION OF THE GROUP FOR THE THREE MONTHS ENDED 31 MARCH 2017 Consolidated Balance Sheet of the Group as at 31 March 2017(All amounts in RMB unless otherwise stated)
Items | As at 31 March 2017 | As at 31 December 2016 (Restated) |
Current assets: | ||
Cash at bank and on hand | 18,333,776,201.58 | 30,590,398,938.82 |
Financial assets at fair value through profit or loss | 928,730.00 | 928,730.00 |
Derivative financial assets | 4,539,042.20 | 4,539,042.20 |
Notes receivable | 7,750,307,441.23 | 9,355,551,771.95 |
Accounts receivable | 76,153,799,837.94 | 59,889,869,634.07 |
Advances to suppliers | 2,455,280,646.23 | 2,361,007,140.15 |
Dividends receivable | 3,642,022.22 | 4,892,022.23 |
Other receivables | 3,116,675,050.64 | 2,826,246,554.53 |
Inventories | 23,340,709,859.56 | 25,448,756,938.03 |
Current portion of non-current assets | 1,565,878,869.76 | 1,508,139,765.66 |
Other current assets | 133,471,819.27 | 456,599,280.36 |
Total current assets | 132,859,009,520.63 | 132,446,929,818.00 |
Non-current assets: | ||
Available-for-sale financial assets | 453,391,596.53 | 461,980,036.08 |
Long-term receivables | 6,281,318,382.64 | 5,178,195,698.29 |
Long-term equity investments | 3,492,746,099.87 | 3,330,929,503.56 |
Investment properties | 463,071,472.14 | 480,623,811.50 |
Fixed assets, at cost | 8,947,797,698.08 | 8,840,347,306.90 |
Less: Accumulated depreciation | 2,932,535,629.86 | 2,813,795,266.19 |
Fixed assets, at net book value | 6,015,262,068.22 | 6,026,552,040.71 |
Less: Impairment provision for fixed assets | 16,812.09 | 16,812.09 |
Fixed assets, net | 6,015,245,256.13 | 6,026,535,228.62 |
Construction in progress | 360,118,165.77 | 383,984,235.97 |
Intangible assets | 3,610,304,740.25 | 3,671,275,350.28 |
Development costs | 34,436,800.07 | 32,109,241.58 |
Goodwill | 3,790,852,506.89 | 3,786,215,913.40 |
Long-term prepaid expenses | 510,463,312.48 | 422,139,465.28 |
Deferred tax assets | 666,870,057.52 | 679,453,376.74 |
Other non-current assets | 844,155,037.62 | 648,787,335.93 |
Total non-current assets | 26,522,973,427.91 | 25,102,229,197.23 |
Total assets | 159,381,982,948.54 | 157,549,159,015.23 |
(All amounts in RMB unless otherwise stated)
Items | As at 31 March 2017 | As at 31 December 2016 (Restated) |
Current liabilities: | ||
Short-term borrowings | 19,367,649,823.46 | 15,073,017,645.33 |
Notes payable | 14,028,941,260.35 | 16,488,614,398.27 |
Accounts payable | 52,417,851,134.84 | 50,257,200,380.20 |
Advances from customers | 842,079,466.98 | 638,528,046.38 |
Employee benefits payable | 496,443,806.95 | 913,420,948.03 |
Taxes payable | 1,192,048,284.29 | 1,224,724,520.60 |
Interest payable | 146,062,260.89 | 427,244,604.39 |
Dividends payable | 28,219,331.52 | 93,770,056.44 |
Other payables | 6,224,966,896.71 | 7,367,647,885.61 |
Current portion of non-current liabilities | 1,412,791,311.56 | 1,296,354,374.37 |
Other current liabilities | 3,050,363,279.87 | 6,047,996,283.12 |
Total current liabilities | 99,207,416,857.42 | 99,828,519,142.74 |
Non-current liabilities: | ||
Long-term borrowings | 3,894,035,790.38 | 3,145,383,389.64 |
Bonds payable | 7,990,830,885.50 | 7,989,915,863.98 |
Long-term payables | 79,574,187.96 | 105,728,020.56 |
Long-term employee benefits payable | 35,833,369.89 | 33,309,599.89 |
Payables for specific projects | 9,921,781.76 | 9,853,243.62 |
Provisions | 183,653.27 | 1,232,081.15 |
Deferred income | 318,245,225.43 | 330,406,572.30 |
Deferred tax liabilities | 595,917,630.48 | 601,327,573.65 |
Other non-current liabilities | 753,748,248.01 | 739,594,180.01 |
Total non-current liabilities | 13,678,290,772.68 | 12,956,750,524.80 |
Total liabilities | 112,885,707,630.10 | 112,785,269,667.54 |
(All amounts in RMB unless otherwise stated)
Items | As at 31 March 2017 | As at 31 December 2016 (Restated) |
Owners' equity (or shareholders' equity): | ||
Paid-in capital (or share capital) | 2,767,095,089.00 | 2,767,095,089.00 |
Capital surplus | 15,005,825,935.21 | 15,029,728,338.79 |
Other comprehensive income | 3,898,231.51 | 7,230,984.90 |
Surplus reserve | 715,868,467.74 | 715,868,467.74 |
Undistributed profits | 14,703,372,130.43 | 13,452,100,179.23 |
Total shareholders' equity attributable to equity holders of the Company | 33,196,059,853.89 | 31,972,023,059.66 |
Minority interest | 13,300,215,464.55 | 12,791,866,288.03 |
Total owners' equity | 46,496,275,318.44 | 44,763,889,347.69 |
Total liabilities and owners' equity | 159,381,982,948.54 | 157,549,159,015.23 |
Sinopharm Group Co. Ltd. published this content on 26 April 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 April 2017 22:23:15 UTC.
Original documenthttp://sinopharm.todayir.com/attachment/2017042606170100002790635_en.pdf
Public permalinkhttp://www.publicnow.com/view/29F388B043950F1EA3C9625947B5E00E9C8D00D7
